• Hikma says "low likelihood" of US approval this year for Advair generic firstwordpharma
    May 12, 2017
    Hikma Pharmaceuticals announced Thursday that the FDA issued a complete response letter regarding the company's filing seeking approval of a generic version of GlaxoSmithKline's asthma and chronic obstructive pulmonary disease therapy Advair Diskus (fluti
PharmaSources Customer Service